H.C. Wainwright lowered the firm’s price target on Sensus Healthcare (SRTS) to $8 from $12 and keeps a Buy rating on the shares. The firm cites the company’s Q2 sales miss for the target cut.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare price target lowered to $6 from $13 at Lake Street
- Sensus Healthcare Reports Q2 2025 Financial Results
- Sensus Healthcare reports Q2 EPS (6c), consensus 1c
- Sensus Healthcare superficial radiation therapy systems get MDSAP certification
- Sensus Healthcare enters strategic agreement with Radiology Oncology Systems